Immunome Inc
IMNM8.680USD
-0.240-2.69%
Fechamento 06/25, 16:00（ET）Cotações atrasadas em 15 min
754.78MValor de mercado
PerdaP/L TTM
Mais detalhes de Immunome Inc Empresa
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Informações da empresa
Código da empresaIMNM
Nome da EmpresaImmunome Inc
Data de listagemOct 02, 2020
Fundado em2015
CEODr. Clay B. Siegall, Ph.D.
Número de funcionários118
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 02
Endereço18702 N. Creek Parkway
CidadeBOTHELL
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal98011
Telefone16103213700
Sitehttps://immunome.com/
Código da empresaIMNM
Data de listagemOct 02, 2020
Fundado em2015
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
Ms. Sandra G. Stoneman
Ms. Sandra G. Stoneman
Chief Legal Officer, General Counsel, Corporate Secretary
Chief Legal Officer, General Counsel, Corporate Secretary
--
--
Dr. Phil Tsai
Dr. Phil Tsai
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Sandra M Swain, M.D.
Dr. Sandra M Swain, M.D.
Independent Director
Independent Director
--
--
Dr. Bob Lechleider, M.D.
Dr. Bob Lechleider, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
Detalhamento da receita
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
9.04M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
T. Rowe Price Investment Management, Inc.
8.68%
Redmile Group, LLC
6.16%
BlackRock Institutional Trust Company, N.A.
5.87%
Enavate Sciences GP, LLC
5.48%
Point72 Asset Management, L.P.
5.01%
Other
68.79%
Investidores
Investidores
Proporção
T. Rowe Price Investment Management, Inc.
8.68%
Redmile Group, LLC
6.16%
BlackRock Institutional Trust Company, N.A.
5.87%
Enavate Sciences GP, LLC
5.48%
Point72 Asset Management, L.P.
5.01%
Other
68.79%
Tipos de investidores
Investidores
Proporção
Investment Advisor
33.48%
Investment Advisor/Hedge Fund
29.43%
Hedge Fund
14.85%
Corporation
8.26%
Research Firm
4.28%
Individual Investor
3.23%
Venture Capital
0.91%
Bank and Trust
0.29%
Pension Fund
0.14%
Other
5.14%
Participação acionária institucional
Atualizado em: seg, 3 de mar
Atualizado em: seg, 3 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
295
69.73M
91.15%
+848.96K
2024Q4
278
64.18M
84.45%
+3.64M
2024Q3
252
62.39M
103.49%
+7.38M
2024Q2
228
58.25M
97.90%
+16.13M
2024Q1
182
46.83M
84.41%
+22.74M
2023Q4
113
32.29M
78.79%
+19.76M
2023Q3
82
6.26M
40.47%
+930.23K
2023Q2
81
5.83M
36.98%
+582.43K
2023Q1
95
4.18M
34.54%
-644.30K
2022Q4
98
4.36M
36.09%
-940.25K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
T. Rowe Price Investment Management, Inc.
5.50M
6.33%
-262.06K
-4.55%
Dec 31, 2024
Redmile Group, LLC
4.83M
5.55%
-61.53K
-1.26%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.74M
4.3%
+134.54K
+3.73%
Dec 31, 2024
Enavate Sciences GP, LLC
3.48M
4%
+3.48M
--
Dec 31, 2024
The Vanguard Group, Inc.
3.00M
3.45%
-128.13K
-4.10%
Dec 31, 2024
EcoR1 Capital, LLC
3.88M
4.46%
--
--
Dec 31, 2024
Fidelity Management & Research Company LLC
3.92M
4.51%
-305.48K
-7.23%
Dec 31, 2024
Opaleye Management Inc.
2.04M
2.35%
+802.50K
+64.85%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
WisdomTree BioRevolution Fund
0.97%
iShares Genomics Immunology and Healthcare ETF
0.71%
ALPS Medical Breakthroughs ETF
0.63%
Virtus LifeSci Biotech Clinical Trials ETF
0.5%
Main Thematic Innovation ETF
0.5%
SPDR S&P Biotech ETF
0.2%
iShares Micro-Cap ETF
0.15%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Nuveen ESG Small-Cap ETF
0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
0.05%
Ver Mais
WisdomTree BioRevolution Fund
Proporção0.97%
iShares Genomics Immunology and Healthcare ETF
Proporção0.71%
ALPS Medical Breakthroughs ETF
Proporção0.63%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.5%
Main Thematic Innovation ETF
Proporção0.5%
SPDR S&P Biotech ETF
Proporção0.2%
iShares Micro-Cap ETF
Proporção0.15%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.13%
Nuveen ESG Small-Cap ETF
Proporção0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
Proporção0.05%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
